AI Drug Discovery: Promise Meets the High Cost of Clinical Proof

AI companies are moving into biotechnology for its large revenues and strong patent and regulatory barriers, according to longevity investor Alex Colville, co-founder of age1. He says AI drug discovery is already speeding up molecule design and routine research work, making it easier and cheaper for small teams to start biotech companies. But the biggest hurdle remains clinical development: proving a drug is safe and effective still requires patients, time, regulatory approval and millions of dollars. AI has not yet made that process substantially cheaper. The article also highlights the early stage of longevity research. Colville estimates that companies focused on ageing have a combined market value of about $15 billion—roughly one-fiftieth of the cancer sector—and says no commercial product has yet proved effective in humans. He expects initial therapies targeting aspects of ageing could emerge within a decade. Loyal is developing a life-extension drug for dogs, while NewLimit is researching epigenetic reprogramming, including work in mice. For biotech and AI investors, the central distinction is between generating promising ideas and proving them in trials. AI drug discovery may broaden the pipeline, but clinical validation remains the costly, slow bottleneck.